

Claims:

1. Tissue factor protein essentially free of substances with which it is associated in its in vivo physiological milieu.

2. Tissue factor protein unaccompanied by associated native glycosylation.

3. The tissue factor protein of claim 1 that is human tissue factor protein.

4. Tissue factor protein wherein a predetermined amino acid residue is substituted, inserted or deleted.

5. The tissue factor protein of claim 4 wherein the transmembrane domain is deleted.

6. The tissue factor protein of claim 3 having the mature tissue factor protein amino acid sequence of Figure 2 in which an amino acid has been inserted, deleted or substituted.

7. The tissue factor protein of claim 6 wherein an arginine or lysine residue has been deleted or substituted by another residue other than lysine or arginine.

8. The tissue factor protein of claim 6 wherein the amino acid residues about 221 to 241 are deleted.

9. A DNA isolate comprising a DNA sequence encoding tissue factor protein.

10. The isolate of claim 9 wherein the DNA is free of introns.

11. The DNA isolate of claim 9 wherein said DNA sequence codes for a polypeptide having the amino acid sequence shown in Figure 2.
12. A recombinant expression vector comprising DNA encoding tissue factor protein of claim 3.
13. A cell transformed with the recombinant expression vector of claim 12.
14. The cell of claim 13 which is a mammalian cell.
15. A process for producing tissue factor protein which comprises constructing an expression vector which comprises DNA encoding tissue factor protein of claim 3, transforming a host cell with the vector and culturing the transformed cell.
16. The process according to claim 15 wherein the host cell is a eukaryotic cell.
17. The process of claim 16 wherein the eukaryotic cell is a mammalian cell.
18. The process of claim 17 wherein the mammalian cell is a human embryonic kidney cell.
19. A pharmaceutical composition useful for the treatment of coagulation disorders comprising a therapeutically effective amount of tissue factor protein of claim 3 and a pharmaceutically acceptable carrier.

35

LC8x431 mhg